Walleye Trading
TGTX icon

Walleye Trading’s TG Therapeutics TGTX Stock Holding History

Walleye Trading’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
24,900
-21,700
-47% -$888K ﹤0.01% 2077
2026
Q1 		$1.55M Buy
46,600
+34,900
+298% +$1.04M ﹤0.01% 1861
2025
Q4 		$349K Sell
11,700
-10,600
-48% -$346K ﹤0.01% 3057
2025
Q3 		$806K Sell
22,300
-43,000
-66% -$1.42M ﹤0.01% 2412
2025
Q2 		$2.35M Buy
65,300
+19,000
+41% +$707K ﹤0.01% 1637
2025
Q1 		$1.83M Sell
46,300
-13,000
-22% -$437K ﹤0.01% 1697
2024
Q4 		$1.78M Buy
59,300
+32,100
+118% +$921K ﹤0.01% 1760
2024
Q3 		$636K Buy
27,200
+12,500
+85% +$273K ﹤0.01% 2372
2024
Q2 		$262K Sell
14,700
-4,600
-24% -$73.4K ﹤0.01% 2920
2024
Q1 		$294K Sell
19,300
-7,700
-29% -$123K ﹤0.01% 3196
2023
Q4 		$461K Buy
27,000
+2,600
+11% +$30.2K ﹤0.01% 3148
2023
Q3 		$204K Buy
24,400
+10,100
+71% +$141K ﹤0.01% 3586
2023
Q2 		$355K Sell
14,300
-9,500
-40% -$245K ﹤0.01% 3037
2023
Q1 		$358K Buy
23,800
+10,100
+74% +$153K ﹤0.01% 3082
2022
Q4 		$162K Sell
13,700
-48,300
-78% -$351K ﹤0.01% 3735
2022
Q3 		$367K Buy
62,000
+46,000
+288% +$302K ﹤0.01% 3176
2022
Q2 		$68K Buy
+16,000
New +$99.9K ﹤0.01% 4236
2022
Q1 		– Sell
-11,600
Closed -$220K – 5911
2021
Q4 		$220K Buy
11,600
+2,600
+29% +$67.5K ﹤0.01% 3781
2021
Q3 		$300K Buy
9,000
+4,900
+120% +$152K ﹤0.01% 3453
2021
Q2 		$159K Buy
+4,100
New +$161K ﹤0.01% 4100
2021
Q1 		– Sell
-7,500
Closed -$390K – 5290
2020
Q4 		$390K Buy
+7,500
New +$253K ﹤0.01% 2903

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Walleye Trading's TGTX Position: Q2 2026 in Review

Walleye Trading increased its TG Therapeutics (TGTX) stake by 265% in Q2 2026, buying an estimated $585K and bringing the position to 19,679 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

Walleye Trading first reported a position in TGTX in Q4 2019 and has held it in 17 quarters since. The position peaked at $1.09M in Q4 2025. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Walleye Trading held 19,679 shares of TG Therapeutics worth $1.08M as of Q2 2026.
  • Walleye Trading bought 14,293 TG Therapeutics shares in Q2 2026, an estimated $585K.
  • TG Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2246 holding.
  • Walleye Trading first reported a position in TG Therapeutics in Q4 2019 and has held it in 17 quarters since.
  • Walleye Trading's TG Therapeutics position peaked at $1.09M in Q4 2025.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.